Kepler Trust Intelligence: New Research

RNS Number : 0810B

Intl. Biotechnology Trust PLC

04 June 2019

 

International Biotechnology Trust: New research          

04/06/19         

·    We discuss the opportunity in International Biotechnology Trust as biotech stocks trade at record low valuations, despite strong prospects for the sector...

Read more

International Biotechnology Trust has seen a strong rebound in performance terms this year after performing relatively well versus peers in 2018, when a strong move toward 'risk-off' sentiment among investors saw equities generally in negative figures, with biotech no exception.

As at 7 May 2019, the trust is up 10.6% in NAV total return terms since the start of January, beating the NASDAQ Biotechnology Index, the peer group and its main rival - Biotech Growth Trust.

Last year, when the MSCI World was down 7.4% and the NASDAQ Biotechnology Index lost 3.2%, the trust lost just 4.4% - outperforming Biotech Growth, which lost 14.3%, by a whacking margin.

The four strong management team, led by Carl Harald Janson, aims to generate long term capital growth and deliver a yield of 4% of NAV via a portfolio of US, European and - to a lesser extent - unquoted investments in the biotech sphere.

In addition to the diversification benefits afforded by the trust's scale, with almost 100 underlying holdings including the unquoted element, the trust's unique focus on avoiding 'binary' risk events has helped it to avoid a number of 'blowups' which have affected its rivals, notably Biogen's abandoned Alzheimer's drug trials which saw it lose more than 30% of its market cap at the end of March this year.

The trust's unquoted portfolio - where the emphasis has shifted from direct investments to investments via a venture fund - is already proving its worth, delivering 1.3x capital invested so far, with the vast majority of its holdings still valued at or close to their original investment value, leaving plenty of room for upside.

The trust has seen significant improvements to its share register, too, with far less concentration and a far broader spread of investors - among whom more than half are now private wealth managers or retail investors. Much of this has been driven by the introduction of a dividend policy which sees the trust pay out a yield of 4% of NAV per annum, converting some of the capital growth it generates to do so.

Whilst converting capital to income does limit the maximum potential for capital growth, the appeal of this yield means the trust has moved in from a persistent discount and now trades at a premium, and has been issuing new shares since Q4 last year - of which more than half a million have come to market. This should, in time, mean the trust's ongoing charges ratio is lower as the trust's fixed costs are spread over a wider shareholder base.

This is an interesting time for the trust. The managers believe that with economic growth on a fairly solid footing going forward, and long-term demand for therapeutic drugs driven by an ageing population, there is a secular tailwind behind biotech companies. We have heard from the trust before that a more 'business friendly' approach taken by the Food and Drugs Administration would lead to greater opportunities among biotech companies, and that seems to be playing out; last year saw more new drugs approved by the FDA than ever before.

Despite this, valuations among biotech companies remain very reasonable - particularly when compared with other sectors in the US. Indeed, while popular wisdom tells us that US equities are expensive after a long rally, the biotech sector is significantly cheaper in p/e terms than other major sectors in the US and far cheaper than the S&P500. Large cap biotech stocks are trading at record low p/e's.

Click here to read the full report

Visit http://www.trustintelligence.co.uk/investor for more high quality independent investment trust research.

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Important information

International Biotechnology Trust is a client of Kepler Trust Intelligence. This material should be considered a marketing communication, and is not independent research.

Kepler Partners is not authorised to make recommendations to Retail Clients. This report is based on factual information only, and is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

This report has been issued by Kepler Partners LLP solely for information purposes only and the views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment. If you are unclear about any of the information on this website or its suitability for you, please contact your financial or tax adviser, or an independent financial or tax adviser before making any investment or financial decisions.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. Persons who access this information are required to inform themselves and to comply with any such restrictions. In particular, this website is exclusively for non-US Persons. The information in this website is not for distribution to and does not constitute an offer to sell or the solicitation of any offer to buy any securities in the United States of America to or for the benefit of US Persons.

This is a marketing document, should be considered non-independent research and is subject to the rules in COBS 12.3 relating to such research. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research.

No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not to be taken as advice to take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's conflict of interest policy is available on request.

Past performance is not necessarily a guide to the future. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that Independent financial advice should be taken before entering into any financial transaction.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is a limited liability partnership registered in England and Wales at 9/10 Savile Row, London W1S 3PF with registered number OC334771.

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority.

About this service

Kepler Trust Intelligence for private investors is not just another news and research website. Our aim is to create a library of high quality investment strategy research, fund analysis and useful guides for private investors, all written in-house by experienced analysts on the investment companies team at Kepler Partners.

We are focused entirely on investment trusts, however we believe that it helps to understand them better if they are placed on a level playing field with OEICs, so you will see comparisons between the two in these pages often.

Our content falls into three categories;

Investment strategy articles are designed to highlight opportunities and developments which are of interest to investment trust investors, positive or negative.

Fund research focuses on individual trusts, examining them in detail to create a snapshot picture which you can use to decide whether or not you want to invest in them.

Educational output is split into simple guides, designed to help beginners understand how investment trusts work, and more complex guides to sectors, regions and strategies which may be of interest to investors.

We do not produce massive amounts of research. Our focus is on quality, not quantity, so we are unlikely to publish more than four or five articles in a given week. For this reason we recommend that you join our mailing list, and we'll send you an email once a week alerting you to what's new on the site. We won't sell your details, and we won't spam you with useless updates.

How are we funded?

Kepler Trust Intelligence is funded entirely by the providers of investment trusts, and is made available freely to any person (professional or private individual) who wants to access it. We clearly disclose all of our relationships, but our research is either paid for directly by specific trusts and their boards, or more generally by the larger asset management groups who pay to have adverts and advertorial. As a result, all of our research should be considered "non-independent" and readers should consider it as marketing.

All of our content is freely available to anyone. We run two versions of the site - one for professionals and one for private investors. The professional site requires readers to volunteer the name of the company they work for and the city / region - so that from a compliance perspective we can be satisfied that all readers really are a professional.

We provide information, not advice

While we hope that you find the research we publish useful, and we believe it will help you to make a more informed decision, but we must of course stress that none of the research published here constitutes a recommendation, or advice, and you should not think that - just because we've published a report on a trust - we believe that trust is a 'buy'. Please read our terms and conditions.

If you want to manage your own investments we hope that this website is a useful source of information which helps you to do that, however if you are in any doubt, you should speak to a financial adviser.

Pascal Dowling

Kepler Partners

This information is provided by RNS

The company news service from the London Stock Exchange

END

 

END

 

 

NRAEANKLEDFNEEF